Clincal analysis of pirarubicin combined chemotherapy in 96 cases of Non-Hodgkin's Lymphoma (NHL)

Objective:To observe the efficacy and adverse response of pirarubicin(THP,T)combination chemotherapy in Non-Hodgkin's lymphoma(NHL).Methods:96 cases of NHL were treat with CYX-THP-VCR-PRED(COTP)regimen.78 patients of newly diagnosed,18 patient of refractory/relapsed.The median follow-up was 41 months.Results:Recent effect :efficacy rate(CR+CP)was 81.1% in newly diagnosed cases and 66.7% in refractory/relapsed cases.Long-term effect:The 3-years overall survival(OS)of the 96 cases of NHL was(55.7±5.6)%,the 5-years OS was(39.8±6.2)%,the median survival time was 39 months.The OS rate at 3-years in newly diagnosed and in refractory/relapsed were(70.6±4.7)%and(41.2±6.5)%,the OS rate at 5-years in newly diagnosed and in refractory/relapsed were(45.3±7.3)%and(18.3±8.0)%.The 3-years OS and the 5-years OS were significantly longer for patients in newly diagnosed than in refractory/relapsed(P0.05).The main adverse reaction,include bone marrow inhibition and gastrointestinal responses.Vein vasculitis occurred in 4 cases.Mild alopecia and liver toxicity occurred in 2 cases.Abnormal electrocardiogram occasionally seen in 1 case.Conclusion:THP combination chemotherapy regimen in NHL was proved here to have a satisfactory outcome with high efficacy and mild adverse response.